Livagen — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Livagen

Also known as: KEDA, Lys-Glu-Asp-Ala, tetrapeptide KEDA

Synthetic tetrapeptide bioregulator (cytogein)

Research chemicalLast updated: October 19, 2026Based on 18 peer-reviewed studies

What it is

Livagen is a short synthetic peptide studied for liver protection, anti-aging, and immune function in Russian research. It's believed to work by reactivating genes that become silenced with age through epigenetic mechanisms. No FDA-approved use; primarily studied in Russian clinical settings with limited independent replication.

The scientific side

Livagen (Lys-Glu-Asp-Ala) is a synthetic tetrapeptide bioregulator derived from the amino acid composition of liver polypeptide preparations. It acts on chromatin, inducing deheterochromatinization (decondensation) of heterochromatic regions in chromosomes of aged cells, thereby reactivating previously silenced genes. It activates ribosomal gene synthetic processes, releases genes repressed by age-related condensation of euchromatic regions, and decondenses pericentromeric structural heterochromatin of chromosomes 1 and 9. Livagen also inhibits enkephalin-degrading enzymes in human serum (IC50 ~20 µM) and does not interact with mu- or delta-opioid receptors. It demonstrates tissue-specific effects consistent with its origin from liver-derived peptide complexes, and modulates digestive enzyme activity in the gastrointestinal tract and non-digestive organs. In hepatocyte cultures, it increases the level of protein synthesis, with the greatest effect observed in cells from old animals.

Class: Synthetic tetrapeptide bioregulator (cytogein)

Administration & storage

Administration
Oral administration (per os) in rat studies (PMID: 16075683)In vitro application to lymphocyte and tissue cultures (PMID: 12533768167052471508525317460203)
Storage
No storage conditions for Livagen are described in the reviewed abstracts.
Cautions
No human pharmacokinetic or safety data were identified in the reviewed abstracts — clinical safety profile is unknown.,Livagen is described as a weakly hydrolyzed peptide not significantly broken down by small intestinal hydrolases in vitro; systemic absorption and metabolic fate in humans are not characterized in available literature.,All chromatin/genomic studies used in vitro lymphocyte culture models; translation to in vivo human effects has not been established in the reviewed abstracts.,Sterile technique is essential for any experimental preparation involving injectable or cell-culture applications, as a general laboratory safety principle.,Combination use with cobalt ions was studied in several in vitro experiments; cobalt ions alone caused significant increases in chromosomal aberrations in old donors — the safety of such combinations in humans is not addressed in available literature.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification